Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 73Rituximab 59Specimen Handling 49Biopsy 42Doxorubicin 41Vincristine 40Magnetic Resonance Spectroscopy 39Prednisone 36venetoclax 28obinutuzumab 27fludarabine 26ibrutinib 22Methotrexate 22Dexamethasone 21Cytarabine 21Lenalidomide 20blinatumomab 19Etoposide 19merphos 17zanubrutinib 16acalabrutinib 16prednylidene 15fludarabine phosphate 15deltacortene 15X-Rays 14Mercaptopurine 14Bendamustine Hydrochloride 14pegaspargase 13Calcium Dobesilate 13CT-P10 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ricolinostat × Lymphoid × 30 days × Clear all
NCT02787369 2026-05-19

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
3 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡